Patient Support Services Contact Us
Image: Coherus Investors

Income Statement

  Year Ending Dec 2020 (Update) Year Ending Dec 2019 (Update) Year Ending Dec 2018 (Update) Year Ending Dec 2017 (Update) Year Ending Dec 2016 (Update)
Net Sales 475.82 356.07 0.00 1.56 190.11
Revenue 475.82 356.07 0.00 1.56 190.11
Total Revenue 475.82 356.07 0.00 1.56 190.11
Cost of Revenue 37.67 17.08 -- -- --
Cost of Revenue, Total 37.67 17.08 -- -- --
Gross Profit 438.16 338.99 -- -- --
Selling/General/Administrative Expense 115.34 116.47 74.72 53.01 39.21
Labor & Related Expense 23.74 20.57 19.46 18.29 12.39
Selling/General/Administrative Expenses, Total 139.08 137.04 94.18 71.30 51.60
Research & Development 142.76 94.19 110.24 162.39 254.44
Total Operating Expense 319.51 248.30 204.42 233.69 306.04
Operating Income 156.32 107.77 -204.42 -232.14 -115.93
Interest Expense - Non-Operating -21.17 -17.60 -9.68 -9.55 -7.98
Interest Expense, Net Non-Operating -21.17 -17.60 -9.68 -9.55 -7.98
Interest Income (Expense), Net-Non-Operating, Total -21.17 -17.60 -9.68 -9.55 -7.98
Other Non-Operating Income (Expense) 0.55 2.61 4.69 3.40 -3.88
Other, Net 0.55 2.61 4.69 3.40 -3.88
Net Income Before Taxes 135.71 92.78 -209.41 -238.29 -127.79
Income Tax – Total 3.46 2.94 -- 0.00 --
Income After Tax 132.24 89.83 -209.41 -238.29 -127.79
Minority Interest 0.00 0.00 0.07 0.12 0.45
Net Income Before Extraordinary Items 132.24 89.83 -209.34 -238.17 -127.34
Extraordinary Item -- -- -- 0.00 --
Total Extraordinary Items -- -- -- 0.00 --
Net Income 132.24 89.83 -209.34 -238.17 -127.34
Income Available to Common Excluding Extraordinary Items 132.24 89.83 -209.34 -238.17 -127.34
Income Available to Common Stocks Including Extraordinary Items 132.24 89.83 -209.34 -238.17 -127.34
Basic Weighted Average Shares 71.41 69.68 65.03 53.13 41.91
Basic EPS Excluding Extraordinary Items 1.85 1.29 -3.22 -4.48 -3.04
Basic EPS Including Extraordinary Items 1.85 1.29 -3.22 -4.48 -3.04
Dilution Adjustment 3.31 -- -- -- --
Diluted Net Income 135.55 89.83 -209.34 -238.17 -127.34
Diluted Weighted Average Shares 83.49 73.19 65.03 53.13 41.91
Diluted EPS Excluding Extraordinary Items 1.62 1.23 -3.22 -4.48 -3.04
Diluted EPS Including Extraordinary Items 1.62 1.23 -3.22 -4.48 -3.04
DPS - Common Stock Primary Issue -- -- -- -- --
Gross Dividends - Common Stock 0.00 0.00 0.00 0.00 0.00
Impairment-Assets Held for Use, Supplemental -- 0.10 3.90 0.60 --
Non-Recurring Items, Total -- 0.10 3.90 0.60 --
Total Special Items -- 0.10 3.90 0.60 --
Normalized Income Before Taxes 135.71 92.88 -205.51 -237.69 -127.79
Effect of Special Items on Income Taxes -- 0.00 0.00 0.00 --
Income Taxes Excluding Impact of Special Items 3.46 2.95 0.00 0.00 --
Normalized Income After Taxes 132.24 89.93 -205.51 -237.69 -127.79
Normalized Income Available to Common 132.24 89.93 -205.44 -237.57 -127.34
Basic Normalized EPS 1.85 1.29 -3.16 -4.47 -3.04
Diluted Normalized EPS 1.62 1.23 -3.16 -4.47 -3.04
Depreciation, Supplemental 2.90 3.30 3.24 3.40 3.00
Interest Expense, Supplemental 21.17 17.60 9.68 9.55 7.98
Rental Expense, Supplemental 3.10 2.40 2.20 2.30 1.70
Stock-Based Compensation, Supplemental 38.16 33.59 34.80 33.40 23.24
Minority Interest, Supplemental 0.00 0.00 0.07 0.12 0.45
Research & Development Expense, Supplemental 142.76 94.19 110.24 162.39 254.44
Audit-Related Fees, Supplemental 1.91 1.69 1.87 1.55 1.81
Audit-Related Fees 0.00 0.00 0.00 0.00 0.00
Tax Fees, Supplemental 0.03 0.00 0.00 0.00 0.00
All Other Fees Paid to Auditor, Supplemental 0.00 0.00 0.00 0.00 0.00
Gross Margin 92.08 95.20 -- -- --
Operating Margin 32.85 30.27 -- -14,918.77 -60.98
Pretax Margin 28.52 26.06 -- -15,314.01 -67.22
Effective Tax Rate 2.55 3.17 -- -- --
Net Profit Margin 27.79 25.23 -- -15,306.56 -66.98
Normalized EBIT 156.32 107.87 -200.52 -231.54 -115.93
Normalized EBITDA 159.22 111.17 -197.28 -228.14 -112.93
For a more complete picture of our financial results, please review our SEC Filings

Copyright Refinitiv